2. GPCR/G Protein
  3. Endothelin Receptor
  4. J-104132

J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications[1][3].

For research use only. We do not sell to patients.

J-104132

J-104132 Chemical Structure

CAS No. : 198279-45-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

J-104132 Related Antibodies

Top Publications Citing Use of Products

View All Endothelin Receptor Isoform Specific Products:

View All Isoforms
ETA ETB

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications[1][3].

IC50 & Target[1]

ETA

0.034 nM (Ki)

ETB

0.104 nM (Ki)

In Vitro

J-104132 potently inhibits ET-1-stimulated phosphatidylinositol hydrolysis (IC50 = 0.059 nM) in human ETA/CHO cells, but fails to stimulate any response by itself at a fully inhibitory concentration (3 nM)[1].
J-104132 (0.001-10 μM) specifically and competitively antagonizes ET-1-induced contractions in rabbit iliac arteries, as it shifts the ET-1 concentration-response curve rightward without affecting the maximal response and does not inhibit contractions induced by KCl or Norepinephrine (HY-13715)[1].
J-104132 (3 nM, 20 min) does not change the Ach (HY-B0282)-induced relaxation in diabetic rats aortae[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

J-104132 Related Antibodies
Parmacokinetics
Species Dose Route Note AUC CLplasma MRT Vd Cmax Tmax F
Rat[1] 0.3 mg/kg i.v. AUC0-10h 246 ng·h/mL 21.3 mL/min/kg 1.12 h 1.27 L/kg / / /
Rat[1] 1 mg/kg i.v. AUC0-10h 936 ng·h/mL 17.9 mL/min/kg 0.89 h 0.97 L/kg / / /
Rat[1] 1 mg/kg p.o. AUC0-10h 408 ng·h/mL / 3.10 h / 178.0 ng/mL 0.25 h 44 %
Rat[1] 10 mg/kg p.o. AUC0-10h 4028 ng·h/mL / 2.82 h / 1754.3 ng/mL 0.75 h /
Rat[1] 3 mg/kg i.v. AUC0-10h 3686 ng·h/mL 16.7 mL/min/kg 0.76 h 0.72 L/kg / / /
Rat[1] 3 mg/kg p.o. AUC0-10h 1252 ng·h/mL / 2.89 h / 476.8 ng/mL 0.40 h 34 %
In Vivo

J-104132 (1, 3, and 10 mg/kg, p.o., single dose) dose-dependently and persistently inhibits the pressor response elicited by big ET-1 in SD rats[1].
J-104132 (0.1, 0.3 and 1 mg/kg, p.o. or i.v., single dose) dose-dependently inhibits the pressor response elicited by ET-1 in SD rats[1].
J-104132 (0.01, 0.03, 0.1 and 0.3 mg/kg/h, i.v., infusion for 2 h) shifts ET-1 dose-response curve to the right in a dose-related manner in dogs[1].
J-104132 (10 mg/kg, i.g., for 2 weeks starting 12 h after balloon injury) decreases the neointima/media ratio in male SD rats and in both male and female ETB-deficient rats, but it has no effect in female wild-type rats[2].
J-104132 (10 mg/kg, p.o., daily for 4 weeks starting 7 weeks after STZ) restores the impaired acetylcholine (ACh)-induced endothelium-dependent relaxation in Streptozotocin (STZ) (HY-13753)-induced diabetic rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SD rats (6-7 weeks) challenged with big ET-1 (0.5 nmol/kg, i.v.)[1]
Dosage: 1, 3 and 10 mg/kg
Administration: p.o., single dose
Result: Almost completely inhibited the pressor response elicited by big ET-1 at 30 min after administration at doses of 1, 3, and 10 mg/kg.
Gradually recovered inhibition of the pressor response elicited by big ET-1 within 3 to 4 h at 1 mg/kg.
Inhibition was maintained for more than 8 hours after administration of the 3 and 10 mg/kg doses.
Animal Model: Male SD rats (200-400 g) challenged with ET-1 (0.5 nmol/kg, i.v.)[1]
Dosage: 0.1, 0.3 and 1 mg/kg
Administration: p.o. or i.v., single dose
Result: Showed dose-related inhibition of ET-1-induced pressor responses after p.o. and i.v. administration.
The relative potencies of J-104132 after p.o. administration were three times less than those after i.v. administration.
Animal Model: Mongtrl dogs (10-15 kg) challenged with ET-1 (1-100 pmol/min for 30 min into the renal artery)[1]
Dosage: 0.01, 0.03, 0.1 and 0.3 mg/kg/h
Administration: i.v., infusion for 2 h
Result: Shifted ET-1 dose-response curve to the right in a dose-related manner.
Shifted the ET-1 dose-response curve approximately 12-fold at 0.03 mg/kg/h.
Animal Model: Mongtrl dogs (10-15 kg) challenged with ET-1 (1-100 pmol/min for 30 min into the brachial artery)[1]
Dosage: 0.01, 0.03, 0.1 and 0.3 mg/kg/h
Administration: i.v., infusion for 2 h
Result: Led to a 15- to 20-fold shift in the dose-response curve at 0.3 mg/kg/h compared with the vehicle.
Shifted the dose-response curve to ET-1 in this vascular bed by more than 20-fold at dose of 0.3 mg/kg/h.
Showed no marked alterations in heart rate, although systemic arterial pressure was observed to slowly decline by approximately 18% over the entire protocol period at the 0.3 mg/kg/h dosage.
Animal Model: Male and female Wild-type and ETB-deficient rats (12-15 weeks) challenged with balloon injury procedure[2]
Dosage: 10 mg/kg
Administration: i.g., for 2 weeks starting 12 h after balloon injury
Result: Markedly decreased the neointima/media ratio in both the wild-type and ETB-deficient male rats.
Markedly decreased the neointima/media ratio in the ETB-deficient female rats but not in the wild-type female rats.
The ETB-deficient rats exhibited significantly increased plasma ET-1 levels, in both males and females compared with the wild-type rats.
Showed no significant differences in ETA or ETB receptor mRNA expression.
Animal Model: Male and female SD rats (10 weeks) challenged with balloon injury procedure[2]
Dosage: 10 mg/kg
Administration: i.g., for 2 weeks starting 12 h after balloon injury
Result: Did not affect body weight, uteri wet weight, or SBP for 2 weeks treatment.
Significantly decreased the neointima/media ratio in the male rats.
Did not affect the neointima/media ratio in female rats.
Significantly increased plasma ET-1 levels compared with vehicle treated group in female SD rats.
Animal Model: Male Wistar rats (7 weeks) injected with STZ (75 mg/kg)[3]
Dosage: 10 mg/kg
Administration: p.o., daily for 4 weeks starting 7 weeks after STZ
Result: Significantly attenuated the impairment of ACh-induced endothelium-dependent relaxation in diabetic rats.
Did not alter plasma glucose, total cholesterol, HDL, VLDL, LDL or triglyceride in diabetic rats.
Revealed that the expression ratio eNOS/GAPDH did not differ among groups.
Reversed the increase of the expression of p22phox mRNA induced by diabetic in rats.
Significantly decreased the elevated level of superoxide anion in the aortae of diabetic rats.
Molecular Weight

531.60

Formula

C31H33NO7
CAS No.
SMILES

O=C(O)[C@H]1[C@H](C(C(C[C@H](C)C(O)=O)=C2)=CC=C2OC)C3=NC(CCCC)=CC=C3[C@@H]1C4=CC=C5OCOC5=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

J-104132 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

J-104132198279-45-7J104132J 104132Endothelin ReceptorETA/ETB receptorET-1vascular contractionshypertensiondiabetic vascular complicationsdiabeticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
J-104132
Cat. No.:
HY-10383
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.